This HTML5 document contains 141 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://dx.doi.org/10.1111/
n8http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q50745427
rdf:type
wikibase:Item
schema:description
artykuł naukowy artigo científico artikel ilmiah 2014年學術文章 научни чланак 2014年學術文章 artikull shkencor 2014 nî lūn-bûn এপ্রিল ২০১৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ wissenschaftlicher Artikel articol științific სამეცნიერო სტატია 2014年学术文章 artigo científico vitskapeleg artikkel vedecký článok مقالة علمية نشرت في أبريل 2014 teaduslik artikkel 2014年學術文章 scientific article published in April 2014 videnskabelig artikel научна статия επιστημονικό άρθρο 2014年學術文章 artículo científico publicado en 2014 наукова стаття, опублікована у квітні 2014 artikulong pang-agham wetenschappelijk artikel tudományos cikk articolo scientifico 2014年学术文章 2014年の論文 article scientific научни чланак vitenskapelig artikkel article científic мақолаи илмӣ naučni članak 2014年學術文章 scientific article published in April 2014 2014年学术文章 artigo científico 2014년 논문 bilimsel makale scienca artikolo מאמר מדעי vědecký článek научная статья 2014年学术文章 bài báo khoa học article scientifique vetenskaplig artikel บทความทางวิทยาศาสตร์ artículu científicu tieteellinen artikkeli scientific article published in April 2014 2014年学术文章 2014年学术文章
p:P577
wds:Q50745427-4AD99420-7236-4166-A05F-A91E7DB49862
wdt:P577
2014-04-01T00:00:00Z
p:P407
wds:Q50745427-C385A7F1-6066-4ADE-94D2-AFC676B06C4A
wdt:P407
wd:Q1860
p:P2860
wds:Q50745427-19696A4F-A500-41DB-9017-33623AB28923 wds:Q50745427-23C82AAF-13D2-4E53-8977-129392C98296 wds:Q50745427-2BBD4D32-AEA1-4303-B719-CECBFF00E654 wds:Q50745427-3A057D24-A1C8-44D1-9900-F3A3E68E6433 wds:Q50745427-464498BF-4297-44B5-82C5-083028722CCD wds:Q50745427-4C6ACE99-02F6-4681-8822-5CB67D27A072 wds:Q50745427-7B071CAD-0AD1-4A91-B703-F87253CC48DA wds:Q50745427-AB6332F6-4C53-4145-96CC-870B874F78B5 wds:Q50745427-B1150E6F-2AB3-4179-A820-5B47CED63CD9 wds:Q50745427-C28543D8-6991-447C-B4A5-51565D3A306A wds:Q50745427-E2B63387-F984-46AD-A7F1-55FDB0565B3E
wdt:P2860
wd:Q43447599 wd:Q42603607 wd:Q38027633 wd:Q38053455 wd:Q38095548 wd:Q35954497 wd:Q44750379 wd:Q46389803 wd:Q39284503 wd:Q34583765 wd:Q51783926
p:P2093
wds:Q50745427-43C407A8-9BB7-4A47-BF48-11D161ED2934 wds:Q50745427-3F9FBC4B-444C-46CB-A011-AB0495EB9D50 wds:Q50745427-7F808865-FC52-4A42-B746-68F5C9A66C6B wds:Q50745427-8CE5EF33-2049-4F3E-97E3-8B4235131991 wds:Q50745427-7338F35A-7406-4C78-B5BB-625C8521CE0E wds:Q50745427-6CB5E572-5675-478F-85C8-B66B668E5502 wds:Q50745427-5AA52DC9-B276-4C27-996B-23FAFB990AC2 wds:Q50745427-0668511E-F5BC-44DF-A240-E422034491A0 wds:Q50745427-1AAD622B-9DA5-433E-AB78-3087BB0019A1 wds:Q50745427-1662E951-3CE4-49F9-9717-87B1FA6BE941 wds:Q50745427-0D1A3332-1FBF-4FBA-9683-EE410221C37D wds:Q50745427-BB153B64-990C-4001-88F7-BBD9E19B4A4A wds:Q50745427-ACC3F5E6-2133-4055-A3E2-E13C38825647 wds:Q50745427-EB9B2BA4-164E-4E43-8051-18DFA1FCAF6C
wdt:P2093
H Nagai C Nishigori M Oka A Kikusawa H Yoshizaki T Bito M Hatakeyama R Nishikawa H Seto T Horikawa A Adachi H Kanki Y Sarayama T Ikeda
rdfs:label
Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis.
skos:prefLabel
Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis.
schema:name
Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis.
p:P1476
wds:Q50745427-FF42CC0D-E3AE-4E85-B1DB-C9C3DC2F57F7
wdt:P1476
Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis.
p:P304
wds:Q50745427-51AB6E84-1637-4881-B93A-61637738B0DA
wdt:P304
922-929
p:P31
wds:Q50745427-BA622CD3-8D3C-4540-A650-3103AD61420D
wdt:P31
wd:Q13442814
p:P921
wds:Q50745427-8F3235D8-3F5B-44FD-B992-242A15A4E3C8 wds:Q50745427-6180AC58-D3E2-455C-8A92-36CF42FB8CE8
wdt:P921
wd:Q348260 wd:Q79460
p:P698
wds:Q50745427-34881BE5-B021-4104-A72A-7196034BC235
wdtn:P698
n8:24329764
wdt:P698
24329764
p:P1433
wds:Q50745427-3B7D5674-4138-49D0-8DDD-743AC3D56156
wdt:P1433
wd:Q4970191
p:P433
wds:Q50745427-C0AD6B57-928F-4DBF-99DF-0B2C19364747
p:P478
wds:Q50745427-146263E1-F576-4FED-B717-9169E278BAC7
wdt:P433
4
wdt:P478
170
p:P356
wds:Q50745427-2EBADB66-9E05-435E-BD2F-FF19BE94E8EC
wdtn:P356
n12:BJD.12791
wdt:P356
10.1111/BJD.12791